Press Release – New York, NY – February 5, 2026 – Sichenzia Ross Ference Carmel LLP announced that it is representing PrimeGen US, Inc., a pioneering biotech company advancing innovative stem cell and exosome therapies, in its recently announced business combination agreement with DT Cloud Star Acquisition Corporation (Nasdaq: DTSQ), a publicly traded special purpose acquisition company. The transaction implies an equity value for PrimeGen US of approximately $1.5 billion (according to the transaction parties) and is subject to various closing conditions.
The SRFC team is led by partners Marc Ross, Sharon Carroll and Matthew Siracusa, with associate Catherine Wu.